Axillary Nodal Response to Neoadjuvant T-DM1 Combined with Pertuzumab in a Prospective Phase II Multi-Institution Clinical Trial [0.03%]
新辅助T-DM1联合帕妥珠单抗腋窝淋巴结阳性HER2阳性乳腺癌患者的II期多中心临床试验的疗效响应研究
Anna Weiss,Qingchun Jin,Adrienne G Waks et al.
Anna Weiss et al.
Background: Patients with ERBB2 (HER2)-positive breast cancer experience high pathologic complete response (pCR) rates after standard neoadjuvant anti-HER2 systemic therapy. We examined axillary pathologic nodal response ...
Impact of Neoadjuvant Paclitaxel/Trastuzumab/Pertuzumab on Breast Tumor Downsizing for Patients with HER2+ Breast Cancer: Single-Arm Prospective Clinical Trial [0.03%]
新辅助帕利昔尤单抗曲妥珠单抗紫杉醇治疗HER2阳性乳腺癌肿瘤缩小的单臂前瞻性临床试验效果分析
Anna Weiss,Tianyu Li,Neelam V Desai et al.
Anna Weiss et al.
Background: The impact of abbreviated neoadjuvant regimens for HER2+ breast cancer on rates of breast conservation therapy (BCT) is unclear. We aimed to determine BCT rates in a single-arm prospective trial of neoadjuvant...
Contemporary Evaluation of Work-Life Integration and Well-Being in US Surgical Residents: A National Mixed-Methods Study [0.03%]
美国手术住院医师工作与生活融合及幸福感的全国混合研究调查的当代评价
Lauren M Janczewski,Joanna T Buchheit,Kimberly B Golisch et al.
Lauren M Janczewski et al.
Background: The demands of surgical training present challenges for work-life integration (WLI). We sought to identify factors associated with work-life conflicts and to understand how programs support WLI. ...
Invited Commentary [0.03%]
invited commentary
Walter E Longo
Walter E Longo
Invited Commentary [0.03%]
invited commentary
Kirk G Sahagian
Kirk G Sahagian
Invited Commentary [0.03%]
invited commentary
Donald T Hess Jr
Donald T Hess Jr
Kurt S Schultz,Anne K Mongiu
Kurt S Schultz
Invited Commentary [0.03%]
invited commentary
Richard J Barth Jr
Richard J Barth Jr
Invited Commentary [0.03%]
特邀评论文章
Donald T Hess Jr
Donald T Hess Jr
Timothy J Eberlein
Timothy J Eberlein